Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Marvin J. Miller

University of Notre Dame, Department: Chemistry

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Hsiri Therapeutics, LLC

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Garrett Moraski invented and patented related compounds at his previous employer, the University of Notre Dame. Hsiri Therapeutics, LLC (“Hsiri”) is a privately held company and has licensed technologies and patents from Notre Dame, including rights to compounds invented by Moraski. The company’s primary focus is to develop new therapies for serious infectious diseases. Through the Notre Dame license, Moraski was given a (b)(4) equity interest in Hsiri. The company is positioned to commercialize and distribute a treatment for tuberculosis should it be developed. The purpose of this research is to design, develop and advance anti-tuberculosis agents.

Listed Research Project
Design, Syntheses and Studies of Novel Antituberculosis Agents

Project Narrative Tuberculosis (TB) is a serious global health risk that infects more than 2,000,000,000 people worldwide and causes a death every 20 seconds! The objective of this proposal is to develop cost effective anti-TB agents. The focus is on studies of new small molecular weight compounds that are easily synthesized, non-toxic, and yet effective at inhibiting TB growth.

Filed on October 25, 2016.

Tell us what you know about Marvin J. Miller's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Marvin J. Miller University of Notre Dame Conflict of Interest Hsiri Therapeutics, LLC Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page